MOTIVATION: Selecting a small number of signature genes for accurate classification of samples is essential for the development of diagnostic tests. However, many genes are highly correlated in gene expression data, and hence, many possible sets of genes are potential classifiers. Because treatment outcomes are poor in advanced chronic myeloid leukemia (CML), we hypothesized that expression of classifiers of advanced phase CML when detected in early CML [chronic phase (CP) CML], correlates with subsequent poorer therapeutic outcome. RESULTS: We developed a method that integrates gene expression data with expert knowledge and predicted functional relationships using iterative Bayesian model averaging. Applying our integrated method to CML, we identified small sets of signature genes that are highly predictive of disease phases and that are more robust and stable than using expression data alone. The accuracy of our algorithm was evaluated using cross-validation on the gene expression data. We then tested the hypothesis that gene sets associated with advanced phase CML would predict relapse after allogeneic transplantation in 176 independent CP CML cases. Our gene signatures of advanced phase CML are predictive of relapse even after adjustment for known risk factors associated with transplant outcomes.
MOTIVATION: Selecting a small number of signature genes for accurate classification of samples is essential for the development of diagnostic tests. However, many genes are highly correlated in gene expression data, and hence, many possible sets of genes are potential classifiers. Because treatment outcomes are poor in advanced chronic myeloid leukemia (CML), we hypothesized that expression of classifiers of advanced phase CML when detected in early CML [chronic phase (CP) CML], correlates with subsequent poorer therapeutic outcome. RESULTS: We developed a method that integrates gene expression data with expert knowledge and predicted functional relationships using iterative Bayesian model averaging. Applying our integrated method to CML, we identified small sets of signature genes that are highly predictive of disease phases and that are more robust and stable than using expression data alone. The accuracy of our algorithm was evaluated using cross-validation on the gene expression data. We then tested the hypothesis that gene sets associated with advanced phase CML would predict relapse after allogeneic transplantation in 176 independent CP CML cases. Our gene signatures of advanced phase CML are predictive of relapse even after adjustment for known risk factors associated with transplant outcomes.
Authors: Paolo Neviani; Ramasamy Santhanam; Rossana Trotta; Mario Notari; Bradley W Blaser; Shujun Liu; Hsiaoyin Mao; Ji Suk Chang; Annamaria Galietta; Ashwin Uttam; Denis C Roy; Mauro Valtieri; Rebecca Bruner-Klisovic; Michael A Caligiuri; Clara D Bloomfield; Guido Marcucci; Danilo Perrotti Journal: Cancer Cell Date: 2005-11 Impact factor: 31.743
Authors: Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson Journal: N Engl J Med Date: 2006-12-07 Impact factor: 91.245
Authors: Mohamad Mohty; Richard M Szydlo; Agnes S M Yong; Jane F Apperley; John M Goldman; Junia V Melo Journal: Blood Date: 2008-06-18 Impact factor: 22.113
Authors: Derek L Stirewalt; Soheil Meshinchi; Kenneth J Kopecky; Wenhong Fan; Era L Pogosova-Agadjanyan; Julia H Engel; Michelle R Cronk; Kathleen Shannon Dorcy; Amy R McQuary; David Hockenbery; Brent Wood; Shelly Heimfeld; Jerald P Radich Journal: Genes Chromosomes Cancer Date: 2008-01 Impact factor: 5.006
Authors: Jerald P Radich; Hongyue Dai; Mao Mao; Vivian Oehler; Jan Schelter; Brian Druker; Charles Sawyers; Neil Shah; Wendy Stock; Cheryl L Willman; Stephen Friend; Peter S Linsley Journal: Proc Natl Acad Sci U S A Date: 2006-02-13 Impact factor: 11.205
Authors: Elke Butt; Katrin Stempfle; Lorenz Lister; Felix Wolf; Marcella Kraft; Andreas B Herrmann; Cristina Perpina Viciano; Christian Weber; Andreas Hochhaus; Thomas Ernst; Carsten Hoffmann; Alma Zernecke; Jochen J Frietsch Journal: Cells Date: 2020-02-14 Impact factor: 6.600
Authors: Jochen J Frietsch; Carolin Kastner; Thomas G P Grunewald; Hardy Schweigel; Peter Nollau; Janine Ziermann; Joachim H Clement; Paul La Rosée; Andreas Hochhaus; Elke Butt Journal: Oncotarget Date: 2014-07-30
Authors: Andreas B Herrmann; Martha-Lena Müller; Martin F Orth; Jörg P Müller; Alma Zernecke; Andreas Hochhaus; Thomas Ernst; Elke Butt; Jochen J Frietsch Journal: J Cell Mol Med Date: 2020-01-19 Impact factor: 5.310